Novartis Takes Aim At Cross-Appeal In Zometa Suit
Novartis Pharmaceuticals Corp. on Monday fought a cross appeal by plaintiffs who had won a $250,000 jury verdict in March over a bone disease allegedly caused by the Swiss drug giant's...To view the full article, register now.
Already a subscriber? Click here to view full article